Tabimorelin

CAS : 193079-69-5

Ref. TR-T003500

Informations sur le produit

• Nom: Tabimorelin
• Synonymes: (R)-alpha-((E)-5-Amino-N,5-dimethyl-2-hexenamido)-N-methyl-N-((R)-alpha-(methylcarbamoyl)phenethyl)-2-naphthalenepropionamide, <span class="text-smallcaps">D</smallcap>-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-<smallcap>D</span>-alanyl-N,N^α-dimethyl-, <span class="text-smallcaps">D</smallcap>-Phenylalaninamide, N-[(2E)-5-amino-5-methyl-1-oxo-2-hexenyl]-N-methyl-3-(2-naphthalenyl)-<smallcap>D</span>-alanyl-N,N^α-dimethyl-, N-[(2E)-5-Amino-5-methyl-1-oxo-2-hexen-1-yl]-N-methyl-3-(2-naphthalenyl)-<span class="text-smallcaps">D</smallcap>-alanyl-N,N^α-dimethyl-<smallcap>D</span>-phenylalaninamide, N-[(2E)-5-amino-5-methylhex-2-enoyl]-N-methyl-3-(naphthalen-2-yl)-D-alanyl-N,Nα-dimethyl-D-phenylalaninamide, Nn 703, Nnc 26-0703, Tabimorelin [INN], Unii-L51Cbe03Kf
• CAS: 193079-69-5

Description

Applications NN703 (Tabimorelin) is an orally active growth hormone (GH) secretagogue intended for use as an alternative to daily injections of GH. In vitro studies in human liver microsomes have indicated that NN703 is a mechanism-based inhibitor of CYP3A4.
References Fabre, G., et al.: Biochem. Pharmacol., 37, 4389 (1988), Thummel, K., et al.: Clin. Pharmacol. Ther., 59, 491 (1996), Yu, D., et al.: J. Clin. Pharmacol., 39, 1203 (1999),

• Marque: TRC

Propriétés chimiques

• Masse moléculaire: 528.68
• Formule: C₃₂H₄₀N₄O₃
• Couleur/Forme: White to Off-White Solid
• InChI: InChI=1S/C32H40N4O3/c1-32(2,33)19-11-16-29(37)35(4)28(22-24-17-18-25-14-9-10-15-26(25)20-24)31(39)36(5)27(30(38)34-3)21-23-12-7-6-8-13-23/h6-18,20,27-28H,19,21-22,33H2,1-5H3,(H,34,38)/b16-11+/t27-,28-/m1/s1
• Code InChI: InChIKey=WURGZWOTGMLDJP-GBDBBNHTSA-N
• SMILES: CNC(=O)[C@@H](Cc1ccccc1)N(C)C(=O)C(Cc1ccc2ccccc2c1)N(C)C(=O)/C=C/CC(C)(C)N